ClinicalTrials.gg
CompletedNCT04642469MERMAID-2Updated Jun 25, 2024Results posted

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

A Phase 3 interventional study of Durvalumab and Placebo in Carcinoma, Non- Small Cell Lung, sponsored by AstraZeneca. Completed at 115 sites in 25 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
67th of 94
30 · median 74
Started
2020
with 13 others
Phase 3
17 of 94
3 open now
Registered
66th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 67th largest by enrollment, is one of 14 that started in 2020, is one of 17 in phase 3, and was the 66th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Read the detailed description

This is a Phase III, randomized, multicenter, double-blind, placebo-controlled, study to evaluate the efficacy and safety of durvalumab adjuvant therapy compared to placebo in patients with completely resected stage II-III NSCLC who have undergone curative intent therapy (complete resection ± neoadjuvant and/or adjuvant therapy), who have no evidence of Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1-defined disease recurrence, and who become MRD+ during surveillance period.

03

Conditions studied

  • Carcinoma, Non- Small Cell Lung

Keywords

  • NCSLC
  • Double-blind
  • PD-L1
  • MEDI4736
  • Durvalumab
  • DFS
  • OS
  • MRD+
  • Lung cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICFs and in the protocol.
  2. Provision of signed and dated, written informed consent form prior to any mandatory study-specific procedures, sampling, and analyses.
  3. Provision of signed and dated written optional genetic informed consent prior to collection of the optional sample for genetic analysis. This consent should be signed at the time of second screening. This optional sample and analyses are separate from the mandatory genetic testing consent included in ICF1.

    The following criteria must have been met at the time of surgery or at the time of the curative intent therapy (first screening):

  4. Age ≥18 years at the time of screening (ICF1);
  5. Male and/or female
  6. confirmed NSCLC with resectable stage II-III disease who have undergone curative intent therapy (complete resection of the primary tumor ± and/or adjuvant therapy) per SoC.

    Select stage IIIB (ie, T3N2 or T4N2) patients will be eligible, provided they are upstaged to T3N2 or T4N2 based on confirmed pathology after surgery. Patients who are staged as T3N2 or T4N2 prior to surgery are not eligible.

  7. A contrast-enhanced CT/MRI scan of the chest and abdomen (including liver and adrenal glands) along with brain MRI (preferred) or brain CT with IV contrast must have been done for surgical planning prior to surgery. It is recommended that patients undergo combined FDG-PET (18F-Fluoro-deoxyglucose positron emission tomography) and CT scan (computerized tomography) within the 6 weeks prior to surgery in order to rule out detectable extrathoracic, extracranial and to assess for potential mediastinal lymph node involvement prior to surgery. If the positron emission tomography (PET) scan was not performed, or data from a PET is not available, patients may still be enrolled into the study provided appropriate imaging (CT/MRI) is performed prior to randomization.
  8. Complete resection of the primary NSCLC is mandatory. Invasive (pre-operative or intra-operative) exploration of hilar and mediastinal lymph nodes must have been performed to confirm primary tumor nodal status (prior to or after surgery). Surgical resection of the primary NSCLC can occur by open thoracotomy or by video-assisted thoracic surgery (VATs) and resection can be achieved by segmentectomy, lobectomy, sleeve resection, bilobectomy or pneumonectomy. Patients undergoing wedge resection are not eligible for this study.

    Criteria for prior systemic chemotherapy/radiotherapy:

  9. Patients should have completed (or be undergoing) curative intent therapy (surgery ± neoadjuvant and/or adjuvant therapy; adjuvant therapy can include PORT) with exceptions noted below:

    Patients who discontinue chemotherapy and/or PORT for toxicity prior to completion of all planned therapy are eligible.

    Patients who have not received any neoadjuvant and/or adjuvant chemotherapy, and meet all other eligibility criteria, may be eligible under the following circumstances:

    • All patients who are eligible for adjuvant chemotherapy MUST be offered adjuvant chemotherapy.
    • The patient has declined adjuvant chemotherapy, and in the opinion of the Investigator, this is the patient's final decision after receiving appropriate information and adequate time to make the decision. The patient's refusal of adjuvant chemotherapy must be documented.
    • If in the view of the Investigator, adjuvant chemotherapy is due to an underlying intercurrent illness/laboratory abnormality, which is not considered reversible within a reasonable timeframe for the patient to be eligible for adjuvant therapy, which must be documented.

    Criteria assessed prior to and at the start of surveillance:

  10. Confirmation of suitable biosamples for WES and central testing. Resected tumor tissue and whole blood samples must be provided to the diagnostic laboratory for WES of tumor and germline DNA, respectively as soon as possible following pathology confirmation. Samples must be sent no later than 1-2 weeks after completion of adjuvant therapy or 3-5 weeks after surgery (if no adjuvant therapy is given) for development of the Sponsor-approved personalized panel for MRD detection at a central reference laboratory. Germline sequencing of whole blood is mandatory. Resected tumor tissue must also be provided for PD-L1 testing at a central reference laboratory (see inclusion criteria 15).
  11. Post-adjuvant therapy or post-surgery (if no adjuvant therapy is given) CT scan of the chest and abdomen (including liver and adrenal glands) and brain MRI [preferred] or brain CT with IV contrast should be available to confirm no evidence of metastasis. If scans were not performed post-curative intent therapy, additional scans must be done prior to start of surveillance.
  12. Consents to be accessible for q6w±3d plasma sample collection for MRD evaluation and for q12w±1w CT scans during the 96-week surveillance period.
  13. The plasma sample that marks the start of surveillance must be collected 8±1 weeks after completion of adjuvant therapy (if administered) or 12±1 weeks after surgery (where adjuvant therapy is not given).

    • A patient who is determined to be MRD- based on analysis of this plasma sample (ie, MRD- at the start of surveillance) may continue in surveillance provided all other eligibility criteria are met.
    • A patient who is determined to be MRD+ based on analysis of this plasma sample (ie, MRD+ at the start of surveillance) may be eligible for immediate randomization provided all other eligibility criteria are met.

    A patient who becomes MRD+ during surveillance is eligible to enter the second screening period and may be randomized in the study if all other eligibility criteria are met.

    Criteria for second screening prior to randomization to treatment:

  14. CT scan of the chest and abdomen (including liver and adrenal glands) and brain MRI [preferred] or brain CT with IV contrast performed within the 28 days ± 7 days prior to randomization to confirm no evidence of 1.1-defined disease recurrence and/or metastasis.
  15. Known tumor PD-L1 status determined at a central reference laboratory testing service using a validated Ventana SP263 PD-L1 immunohistochemistry (IHC) assay prior randomization. Patients with unknown PD-L1 status are not eligible for the study.
  16. WHO/ (ECOG) performance status (PS) 0-1.
  17. Complete post-operative wound healing must have occurred prior to randomization; patients must have recovered from all acute, reversible toxic effects from prior treatments (excluding alopecia) that could potentially adversely impact further administration of durvalumab/placebo according to the Investigator's judgment.
  18. Must have recovered from all acute, reversible toxic effects from chemotherapy that could potentially adversely impact further administration of durvalumab or placebo according to the Investigator's judgment
  19. Adequate organ and marrow function as described in the protocol.
  20. Must have a of at least 12 weeks Weight
  21. Body weight >30 kg Inclusion criteria assessed prior to entering the observation period
  22. No evidence of RECIST 1.1-defined disease recurrence or metastasis confirmed by CT scan of the chest and abdomen (including liver and adrenal glands) and a brain MRI (preferred) or brain CT with IV contrast.
  23. MRD- status, as determined by testing the last plasma sample collected during the 96-week surveillance period.

Exclusion criteria

Exclusion Criteria:

Diagnostics assessments:

  1. EGFR and/or ALK mutant as assessed either from the tumor taken prior to surgery or the resected tumor tissue. Testing must be performed using a wellvalidated, local regulatory-approved test. EGFR/ALK may be tested centrally if local testing is unavailable.
  2. Mixed small cell and NSCLC histology.
  3. Require re-resection or are deemed to have unresectable NSCLC by amultidisciplinary evaluation that must include a thoracic surgeon who performs lung cancer surgery as a significant part of their practice.
  4. Baseline imaging demonstrating unequivocal evidence of 1.1-defined disease recurrence or evidence of clinical recurrence outside of imaging prior to randomization. In the event of lymphadenopathy on imaging that would lead to exclusion, histopathological confirmation of lymph node should be obtained prior to excluding a patient from the study. If pathological confirmation of lymph node metastasis is not technically feasible and imaging appearance are deemed unequivocal for relapse, the patient will be excluded.

    Medical conditions

  5. History of allogeneic organ or bone marrow transplantation.
  6. Non-leukocyte-depleted whole blood transfusion in 120 days of genetic sample collection
  7. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or

    Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    Patients with vitiligo or alopecia Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement Any chronic skin condition that does not require systemic therapy Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician Patients with celiac disease controlled by diet alone

  8. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active ILD, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written .
  9. History of another primary except for Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated carcinoma in-situ without evidence of disease
  10. History of active primary immunodeficiency
  11. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), virus (HBV) (known positive HBV surface antigen (HBsAg) result), virus (HCV), or (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  12. Known allergy or to any of the IPs or any of the IP Prior/concomitant therapy
  13. Received any IO therapy in the setting or any prior exposure to durvalumab.
  14. Received any radiotherapy in the neoadjuvant setting.
  15. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.
  16. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP.
  17. Receipt of within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.
  18. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.
  19. Current or prior use of medication within 14 days before the first dose of IP. The following are exceptions to this criterion:

    Intranasal, inhaled, topical , or local steroid injections (eg, intra-articular injection) Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) Prior/concurrent clinical study experience

  20. Previous IP assignment in the present study
  21. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  22. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.

    Other exclusions

  23. Female patients who are pregnant or breastfeeding.

    • Female patients who become pregnant during the study will be withdrawn from surveillance and are not eligible for randomization.
  24. Male or female patients of who are not willing to employ effective at the time of entry into second screening (initiated with the signing of ICF2a) until 90 days after the last dose of IP (See Appendix H).
  25. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Durvalumab

    Intravenous administration of Durvalumab

    Drug: Durvalumab

  • Placebo comparator
    Placebo

    Intravenous administration of placebo

    Other: Placebo

Interventions

  • Intravenous administration of Durvalumab

    Also known as: Medi4736

  • OtherPlacebo

    Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Disease-free Survival (DFS)

    DFS was defined as the time from the date of randomization until any one of the following events, whichever occurred first: Date of disease recurrence using Investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 OR Date of death from any cause.

    Time frame: Every 8 weeks (q8w) ± 1 week until Week 48, then every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or follow-up, up to 16.6 months

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event was any untoward medical occurrence (other than progression of the malignancy under evaluation) in a participant or clinical study participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An SAE was an AE that occurred during any study phase and fulfilled one or more of the following criteria: Resulted in death, was immediately life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect, was an important medical event that might jeopardize the participant or might require medical treatment to prevent one of the outcomes listed above, AEs for malignant tumors reported during a study, malignant tumors that - as part of normal, if rare, progression - underwent transformation.

    Time frame: From start of study treatment (Day 1) up to 90 days after last dose of study treatment, approximately 21.4 months

07

Results

Posted Jun 25, 2024
Limitations and caveats
The Sponsor closed enrollment to the study early due to treatment landscape changes. Interpretation of study outcomes were limited by the resulting small sample size and limited duration of follow-up.

Participant flow

This Phase III multicenter, double-blind, placebo-controlled study was conducted in participants with Stage II to III non-small cell lung cancer (NSCLC) at 21 sites in 13 countries (Australia, Brazil, Czech Republic, France, Greece, Hungary, Israel, Italy, Japan, Spain, Taiwan, Turkey, and United States). First participant was enrolled on 30-Nov-2020 and final data cut-off (DCO) date was 31 May 2023.

Participant flow — Overall Study
MilestoneDurvalumabPlacebo
Started1515
Completed01
Not completed1514
Withdrew: Failure to meet inclusion/exclusion criteria10
Withdrew: Death12
Withdrew: Study/site closed following amendment 11111
Withdrew: Other11
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryDisease-free Survival (DFS)

DFS was defined as the time from the date of randomization until any one of the following events, whichever occurred first: Date of disease recurrence using Investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 OR Date of death from any cause.

Time frame:
Every 8 weeks (q8w) ± 1 week until Week 48, then every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or follow-up, up to 16.6 months
Reported as:
Median · Months
Disease-free Survival (DFS)
MonthsDurvalumabPlacebo
Disease-free Survival (DFS)3.9 (3.515 to NA)2.0 (1.643 to 3.910)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event was any untoward medical occurrence (other than progression of the malignancy under evaluation) in a participant or clinical study participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An SAE was an AE that occurred during any study phase and fulfilled one or more of the following criteria: Resulted in death, was immediately life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect, was an important medical event that might jeopardize the participant or might require medical treatment to prevent one of the outcomes listed above, AEs for malignant tumors reported during a study, malignant tumors that - as part of normal, if rare, progression - underwent transformation.

Time frame:
From start of study treatment (Day 1) up to 90 days after last dose of study treatment, approximately 21.4 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsDurvalumabPlacebo
Any AEs1310
Any SAEs11

Adverse events

Collected over Treatment emergent Adverse events (TEAEs) were collected from start of study treatment (Day 1) up to 90 days after last dose of study treatment, approximately 21.4 months. All-cause mortality was collected from start of randomization (Day 0) up to completion of study, approximately 30 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab1/15 (6.7%)1/14 (7.1%)13/14 (92.9%)
Placebo2/15 (13.3%)1/15 (6.7%)10/15 (66.7%)
Most frequent serious events
Most frequent serious events
EventDurvalumabPlacebo
Autoimmune hepatitisHepatobiliary disorders1/140/15
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/141/15
Most frequent other events
Showing 10 of 54
Most frequent other events
EventDurvalumabPlacebo
HypothyroidismEndocrine disorders4/140/15
AstheniaGeneral disorders3/140/15
PruritusSkin and subcutaneous tissue disorders3/140/15
ArthralgiaMusculoskeletal and connective tissue disorders2/140/15
RashSkin and subcutaneous tissue disorders2/141/15
HyperthyroidismEndocrine disorders2/140/15
DiarrhoeaGastrointestinal disorders2/141/15
TachycardiaCardiac disorders0/142/15
Periodontal diseaseGastrointestinal disorders1/140/15
StomatitisGastrointestinal disorders1/140/15

Baseline characteristics

The Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(Years)DurvalumabPlaceboTotal
Mean59.3 ± 8.666.7 ± 10.363.0 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)DurvalumabPlaceboTotal
Female7411
Male81119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DurvalumabPlaceboTotal
Asian358
White7714
Other101
Missing437
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DurvalumabPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino151530
08

Study locations

115 sites
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Gainesville, Florida 32605, United States
  • Research Site
    Punta Gorda, Florida 33980, United States
  • Research Site
    Louisville, Kentucky 40241, United States
  • Research Site
    Minneapolis, Minnesota 55404, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Buenos Aires, C1125ABD, Argentina
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Hasselt, 3500, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    Vitoria, 29043-260, Brazil
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Saint John, New Brunswick E2L 4L2, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Olomouc, 77900, Czechia
  • Research Site
    Ostrava, 703 00, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Marseille, 13915, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    St Herblain, 44805, France
  • Research Site
    Strasbourg Cedex, 67091, France
  • Research Site
    Athens, 11526, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Heraklion, 71110, Greece
  • Research Site
    Holargos, Athens, 155 62, Greece
  • Research Site
    Larissa, 41110, Greece
  • Research Site
    Thessaloniki, 54645, Greece
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Jordan, Hong Kong
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Gyöngyös - Mátraháza, 3200, Hungary
  • Research Site
    Győr, 9024, Hungary
  • Research Site
    Szolnok, 5004, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Bengaluru, 560099, India
  • Research Site
    New Delhi, 11029, India
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Kfar Saba, 4428164, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Ramat-Gan, 52621, Israel
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Monza, 20052, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Bunkyo-ku, 160-0023, Japan
  • Research Site
    Hiroshima-shi, 734-8551, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Koto-ku, 135-8550, Japan
  • Research Site
    Osaka-shi, 534-0021, Japan
  • Research Site
    Osaka-shi, 541-8567, Japan
  • Research Site
    Sakai-shi, 591-8555, Japan
  • Research Site
    Sendai-shi, 980-0873, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Yokohama-shi, 241-8515, Japan
  • Research Site
    Cheongju-si, 28644, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Suwon, 16247, Korea, Republic of
  • Research Site
    Breda, 4818 CK, Netherlands
  • Research Site
    Maastricht, 6202 AZ, Netherlands
  • Research Site
    Zwolle, 8025 AB, Netherlands
  • Research Site
    Lima, Lima 32, Peru
  • Research Site
    Lima, LIMA 34, Peru
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Tomaszów Mazowiecki, 97-200, Poland
  • Research Site
    Warszawa, 02-781, Poland
  • Research Site
    Moscow, 105229, Russian Federation
  • Research Site
    Moscow, 115478, Russian Federation
  • Research Site
    Novosibirsk, 630108, Russian Federation
  • Research Site
    Saint Petersburg, 191036, Russian Federation
  • Research Site
    Saint Petersburg, 197758, Russian Federation
  • Research Site
    Singapore, 119228, Singapore
  • Research Site
    Singapore, 169610, Singapore
  • Research Site
    Singapore, 308433, Singapore
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Oviedo, 33011, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Santiago de Compostela, 15706, Spain

Showing the first 100 of 115 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in May 2023, 30 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 30 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2020
First posted
Nov 24, 2020
StartActual
Nov 30, 2020
Primary completionActual
May 31, 2023
CompletionActual
Jan 15, 2024
Results first posted
Jun 25, 2024
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04642469
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 24, 2020
Start date
Nov 30, 2020
Primary completion
May 31, 2023
Completion
Jan 15, 2024
Results posted
Jun 25, 2024
Last update
Jun 25, 2024

Study contacts

David Spigel
principal investigator · SCRI Development Innovations, LLC
Charles Swanton
principal investigator · Francis Crick Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion